COVID-19 erased the regulatory and trial-related hurdles that Moderna could never surmount before. Yet, how did Moderna know that COVID-19 would create those conditions months before anyone else, and why did they later claim that their vaccine being tested in NIH trials was different than their commercial candidate? In late 2019, the biopharmaceutical company Moderna was facing a series of challenges that not only threatened its ability to ever take a product to market, and thus turn a profit, but its very existence as a company. There were multiple warning signs that Moderna was essentially another Theranos-style fraud, with many of these signs growing in frequency and severity as the decade drew to a close. Part I of this three-part series explored the disastrous circumstances in which Moderna found itself at that time, with the company’s salvation hinging on the hope of a divine miracle, a “Hail Mary” save of sorts, as stated by one former Moderna employee.
If You Find EarthNewspaper.com Informative, Please Make A Contribution
Donate today and support the work I do seven days a week. Each day I publish more than a dozen news articles and videos, from honest, independent and reliable sources, on a completely ad-free website. There are four ways you may donate: credit card, check, bank wire, or SubscribeStar. I, Mark R. Elsis, thank you in advance for your gracious generosity, so that EarthNewspaper.com All The Honest News Fit To Publish may keep growing quickly.